Reporting
CTNPT 045: Immune Response to COVID-19 Vaccination in People with HIV
Vaccines in a Time of Dual Pandemic: COVID-19 Vaccine in People with HIV
Learn MoreReporting
Vaccines in a Time of Dual Pandemic: COVID-19 Vaccine in People with HIV
Learn MoreReporting
Immunogenicity outcomes in people living with HIV following vaccination for COVID-19 (HIV-COV)
Learn MoreOngoing
The impact of COVID-19 on persons with HIV in Canada: Data from the HIV/HCV co-infection/CCC (CTN 222) and HIV aging cohorts (CTN 314)
Learn MoreCTN Trials have been approved by the Community Advisory Committee of the Canadian HIV Trials Network and the Network’s Scientific Review Committee, or other national peer-review panels such as those at the Canadian Institutes of Health Research and the U.S. National Institutes of Health. CTNPT studies are small-scale investigations designed to determine the feasibility of research concepts, and do not all go through the regular CTN clinical trial review process. For information on the benefits and risks of participating in HIV clinical trials, call CATIE toll-free at 1-800-263-1638.